- Home
- SSSS vs INZY Comparison
SSSS vs INZY Comparison
Compare SSSS & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- INZY
- Stock Information
- Founded
- SSSS 2010
- INZY 2015
- Country
- SSSS United States
- INZY United States
- Employees
- SSSS N/A
- INZY N/A
- Industry
- SSSS Finance: Consumer Services
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- SSSS Finance
- INZY Health Care
- Exchange
- SSSS Nasdaq
- INZY Nasdaq
- Market Cap
- SSSS 143.5M
- INZY 165.1M
- IPO Year
- SSSS N/A
- INZY 2020
- Fundamental
- Price
- SSSS $5.83
- INZY $2.94
- Analyst Decision
- SSSS Buy
- INZY Strong Buy
- Analyst Count
- SSSS 2
- INZY 7
- Target Price
- SSSS $6.00
- INZY $16.14
- AVG Volume (30 Days)
- SSSS 245.8K
- INZY 920.5K
- Earning Date
- SSSS 11-07-2024
- INZY 11-05-2024
- Dividend Yield
- SSSS N/A
- INZY N/A
- EPS Growth
- SSSS N/A
- INZY N/A
- EPS
- SSSS N/A
- INZY N/A
- Revenue
- SSSS $5,903,895.00
- INZY N/A
- Revenue This Year
- SSSS N/A
- INZY N/A
- Revenue Next Year
- SSSS $6.05
- INZY N/A
- P/E Ratio
- SSSS N/A
- INZY N/A
- Revenue Growth
- SSSS 5.43
- INZY N/A
- 52 Week Low
- SSSS $3.32
- INZY $2.39
- 52 Week High
- SSSS $6.65
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- SSSS 55.63
- INZY 39.38
- Support Level
- SSSS $5.51
- INZY $2.65
- Resistance Level
- SSSS $6.65
- INZY $3.28
- Average True Range (ATR)
- SSSS 0.39
- INZY 0.25
- MACD
- SSSS -0.06
- INZY 0.07
- Stochastic Oscillator
- SSSS 39.71
- INZY 39.07
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.